Orion has been operating in pharmaceutical industry for over 100 years. Respiratory therapy has been one of our focus areas since the 1990s, and our first pulmonary medication was made available to the market in 1993. As a fully integrated pharmaceutical company, we have a well-established commercial presence in the European respiratory space.
Partnerships and alliances throughout the value chain are strategically important for us as we build on our competitive strengths. We collaborate with a number of pharmaceutical companies and industry operators in several countries.
We can provide a complete value chain for proprietary dry powder inhalers with active pharmaceutical ingredients (APIs).
We have over three decades of experience in pulmonary pharmaceutical development, producing inhalers, dry powder formulations and APIs as well as conducting respiratory clinical trials. Easyhaler® products have been in use for nearly 7 million patient years.
Orion has extensive experience in commercial scale manufacturing and supply as well as commercial excellence, pricing and market access especially in our key markets in Europe. Additionally, through a partnership with a leading digital health company, the first digital solutions for enhanced treatment have been developed.
Successful partnership management is a business priority for us.
Orion is constantly seeking and evaluating potential new partnerships.
